|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of
tumours of the central nervous system. Acta Neuropathol.
114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Hateer H, Souhami L, Roberge D, Maestro
RD, Leblanc R, Eldebawy, et al: Low-grade oligodendroglioma: an
indolent but incurable disease? J Neurosurg. 111:265–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mason WP: Oligodendroglioma. Curr Treat
Options Neurol. 7:305–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaw EG, Berkey B, Coons SW, Bullard D,
Brachman D, Buckner JC, et al: Recurrence following
neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical
trial. J Neurosurg. 109:835–841. 2008. View Article : Google Scholar
|
|
5
|
Pignatti F, van den Bent M, Curran D,
Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M,
Vecht C and Karim AB; European Organization for Research and
Treatment of Cancer Brain Tumor Cooperative Group; European
Organization for Research and Treatment of Cancer Radiotherapy
Cooperative Group. Prognostic factors for survival in adult
patients with cerebral low-grade glioma. J Clin Oncol.
20:2076–2084. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jenkins RB, Blair H, Ballman KV, Giannini
C, Arusell RM, Law M, et al: At(1;19)(q10;p10) mediates the
combined deletions of 1p and 19q and predicts a better prognosis of
patients with oligodendroglioma. Cancer Res. 66:9852–9861. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Felsberg J, Erkwoh A, Sabel MC, Kirsch L,
Fimmers R, Blaschke B, et al: Oligodendroglial tumours: refinement
of candidate regions on chromosome arm 1p and correlation of 1p/19q
status with survival. Brain Pathol. 14:121–130. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okamoto Y, Di Patre PL, Burkhard C,
Horstmann S, Jourde B, Fahey M, et al: Population-based study on
incidence, survival rates, and genetic alterations of low-grade
diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol.
108:49–56. 2004. View Article : Google Scholar
|
|
9
|
van den Bent MJ, Looijenga LH, Langenberg
K, Dinjens W, Graveland W, Uytdewilligen L, et al: Chromosomal
anomalies in oligodendroglial tumours are correlated with clinical
features. Cancer. 97:1276–1284. 2003.PubMed/NCBI
|
|
10
|
Natsume A, Kondo Y, Ito M, Motomura K,
Wakabayashi T and Yoshida J: Epigenetic aberrations and therapeutic
implications in gliomas. Cancer Sci. 101:1331–1336. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter
hypermethylation is a common event in primary human neoplasia.
Cancer Res. 59:793–797. 1999.PubMed/NCBI
|
|
12
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, et al: Inactivation of the
DNA-repair gene MGMT and the clinical response of gliomas to
alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar
|
|
13
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, et al: MGMT gene silencing and benefit
from temozolomide in glioblastoma. N Engl J Med. 352:997–1003.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alaminos M, Dávalos V, Ropero S, Setién F,
Paz MF, Herranz M, et al: EMP3, a myelin-related gene located in
the critical 19q13.3 region, is epigenetically silenced and
exhibits features of a candidate tumour suppressor in glioma and
neuroblastoma. Cancer Res. 65:2565–2571. 2005. View Article : Google Scholar
|
|
15
|
Fumoto S, Tanimoto K, Hiyama E, Noguchi T,
Nishiyama M and Hiyama K: EMP3 as a candidate tumor suppressor gene
for solid tumors. Expert Opin Ther Targets. 13:811–822. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qu M, Jiao H, Zhao J, Ren ZP, Smits A,
Kere J and Nistér M: Molecular genetic and epigenetic analysis of
NCX2/SLC8A2 at 19q13.3 in human gliomas. Neuropathol Appl
Neurobiol. 36:198–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor V and Suter U: Epithelial membrane
protein-2 and epithelial membrane protein-3: two novel members of
the peripheral myelin protein 22 gene family. Gene. 175:115–120.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tews B, Felsberg J, Hartmann C, Kunitz A,
Hahn M, Toedt G, et al: Identification of novel
oligodendroglioma-associated candidate tumour suppressor genes in
1p36 and 19q13 using microarray-based expression profiling. Int J
Cancer. 119:792–800. 2006. View Article : Google Scholar
|
|
19
|
Yim JH, Kim YJ, Ko JH, Cho YE, Kim SM, Kim
JY, et al: The putative tumour suppressor gene GLTSCR2 induces
PTEN-modulated cell death. Cell Death Differ. 14:1872–1879. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li KK, Pang JC, Chung NY, Ng YL, Chan NH,
Zhou L, et al: EMP3 overexpression is associated with
oligodendroglial tumours retaining chromosome arms 1p and 19q. Int
J Cancer. 120:947–950. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kunitz A, Wolter M, van den Boom J,
Felsberg J, Tews B, Hahn M, et al: DNA hypermethylation and
aberrant expression of the EMP3 gene at 19q13.3 in human gliomas.
Brain Pathol. 17:363–370. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Molinari C, Iorio P, Medri L, Ballardini
M, Guiducci G, Cremonini AM, et al: Chromosome 1p and 19q
evaluation in low-grade oligodendrogliomas: A descriptive study.
Int J Mol Med. 25:145–151. 2010.PubMed/NCBI
|
|
23
|
Brandes AA, Tosoni A, Cavallo G, Reni M,
Franceschi E, Bonaldi L, et al: Correlations between
O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to
temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. J Clin Oncol. 24:4746–4753.
2006.PubMed/NCBI
|
|
24
|
Ichimura K, Pearson DM, Kocialkowski S,
Bäcklund LM, Chan R, Jones DT and Collins VP: IDH1 mutations are
present in the majority of common adult gliomas but are rare in
primary glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: a novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giannini C, Burger PC, Berkey BA,
Cairncross JG, Jenkins RB, Mehta M, et al: Anaplastic
oligodendroglial tumours: refining the correlation among
histopathology, 1p 19q deletion and clinical outcome in Intergroup
Radiation Therapy Oncology Group Trial 9402. Brain Pathol.
18:360–369. 2008. View Article : Google Scholar
|
|
27
|
Bello MJ, Leone PE, Vaquero J, de Campos
JM, Kusak ME, Sarasa JL, et al: Allelic loss at 1p and 19q
frequently occurs in association and may represent early oncogenic
events in oligodendroglial tumours. Int J Cancer. 64:207–210. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith JS, Alderete B, Minn Y, Borell TJ,
Perry A, Mohapatra G, et al: Localization of common deletion
regions on 1p and 19q in human gliomas and their association with
histological subtype. Oncogene. 18:4144–4152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kaneshiro D, Kobayashi T, Chao ST, Suh J
and Prayson RA: Chromosome 1p and 19q deletions in glioblastoma
multiforme. Appl Immunohistochem Mol Morphol. 17:512–516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nigro JM, Misra A, Zhang L, Smirnov I,
Colman H, Griffin C, et al: Integrated array-comparative genomic
hybridization and expression array profiles identify clinically
relevant molecular subtypes of glioblastoma. Cancer Res.
65:1678–1686. 2005. View Article : Google Scholar
|
|
31
|
Ruano Y, Mollejo M, Ribalta T, Fiaño C,
Camacho FI, Gómez E, et al: Identification of novel candidate
target genes in amplicons of Glioblastoma multiforme tumors
detected by expression and CGH microarray profiling. Mol Cancer.
5:392006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fumoto S, Hiyama K, Tanimoto K, Noguchi T,
Hihara J, Hiyama E, et al: EMP3 as a tumor suppressor gene for
esophageal squamous cell carcinoma. Cancer Lett. 274:25–32. 2009.
View Article : Google Scholar : PubMed/NCBI
|
